Research shows that DHP107, a new cancer medicine, works the same way in the body whether patients eat food or not. According to Gram Research analysis of a 2026 clinical trial with 25 cancer patients, the drug’s blood levels were 101-105% similar between fed and fasted conditions, meeting medical standards for no food effect. This means patients can take DHP107 whenever is convenient without worrying about meal timing.
Researchers tested a new cancer medicine called DHP107 to see if eating food changed how the body absorbs it. According to Gram Research analysis, 25 patients with advanced cancer took the drug either on an empty stomach or after a big meal. The study found that food didn’t significantly change how much medicine got into the bloodstream or how fast it worked. This is good news because it means patients can take DHP107 whenever is easiest for them, without worrying about timing meals around their medication.
Key Statistics
A 2026 randomized controlled trial of 25 patients with advanced solid tumors found that DHP107’s peak blood concentration was 101% when taken after a high-fat meal compared to fasting, meeting criteria for no food effect.
In the same 2026 trial of DHP107, the total drug exposure over 72 hours was 103% when patients ate before dosing versus fasting, demonstrating consistent absorption regardless of food intake.
Among 25 cancer patients taking DHP107 in a 2026 crossover study, vomiting occurred in 30.8% of those who fasted before the dose but only 8.3% of those who ate first, suggesting food might improve tolerability.
A 2026 Phase 1 trial of DHP107 in 25 advanced cancer patients showed that diarrhea was the most common side effect at 61.5% in the fasted group and 41.7% in the fed group.
The Quick Take
- What they studied: Whether eating food before or after taking DHP107 (a new cancer medicine) changes how much of the drug gets into the patient’s body and how well it works
- Who participated: 25 patients with advanced solid tumors (cancers that have spread). Half took the drug while fasting, then later with food. The other half did the opposite order.
- Key finding: The amount of DHP107 in the bloodstream was nearly identical whether patients ate food or not. Geometric mean ratios showed paclitaxel exposure was 101-105% across fed and fasted conditions, meeting no food effect criteria.
- What it means for you: Patients taking DHP107 don’t need to plan their meals around the medication. They can take it whenever is convenient, with or without eating. However, this is early-stage research in a small group, so more studies may be needed to confirm these findings in larger populations.
The Research Details
This was a Phase 1 clinical trial, which means it was one of the earliest tests of this drug in humans. The study used a crossover design, where each patient received the drug twice—once on an empty stomach and once after eating a high-fat meal. The order was randomly assigned, so some patients fasted first while others ate first. This design is powerful because each person serves as their own comparison, reducing the effect of individual differences.
Researchers measured how much DHP107 stayed in patients’ bloodstreams over 72 hours after each dose. They tracked two key measurements: the peak amount (called Cmax) and the total amount over time (called AUC). They also watched for side effects like nausea, vomiting, and low white blood cell counts.
The study lasted two cycles of treatment, with patients receiving DHP107 twice daily on specific days. This allowed researchers to see both immediate effects and longer-term safety patterns.
Understanding whether food affects a cancer drug is crucial for patient quality of life. If food significantly changed how the body absorbs the medicine, patients would need to follow strict eating schedules, which is difficult and stressful. This study’s crossover design is particularly valuable because it controls for individual differences—each patient’s response to food is compared to their own response without food, making the results more reliable.
This study has several strengths: it was randomized (reducing bias), used objective measurements of drug levels in the blood, and included safety monitoring. However, the sample size is small (25 patients), which is typical for Phase 1 trials but limits how much we can generalize. The study was open-label, meaning both patients and researchers knew who was in which group, which could introduce some bias. The findings are specific to DHP107 and may not apply to other cancer drugs.
What the Results Show
The main finding was that food had virtually no effect on how much DHP107 entered the bloodstream. When patients ate a high-fat meal before taking the drug, the peak concentration was 101% of the fasted level—essentially identical. The total drug exposure over 72 hours was 103% when fed versus fasted, and over the entire drug elimination period it was 105%. These small differences fall well within the range considered “no food effect” by medical standards.
This consistency held true for paclitaxel (the active ingredient) and its metabolites (breakdown products). The study met its primary objective, demonstrating that DHP107’s novel lipid formulation allows it to be absorbed reliably regardless of food intake. This is a significant advantage over some older cancer drugs that require specific eating instructions.
The results suggest that DHP107’s special formulation—designed without Cremophor EL, a problematic ingredient in older paclitaxel versions—provides stable absorption in various conditions. This stability is important for cancer treatment, where consistent drug levels help maximize effectiveness and minimize unpredictable side effects.
Safety data showed that side effects were common but manageable. Diarrhea was the most frequent side effect (61.5% in fasted-fed group, 41.7% in fed-fasted group). Vomiting occurred in 30.8% of the fasted-fed group but only 8.3% of the fed-fasted group, suggesting that eating before the dose might reduce nausea. Low white blood cell counts (neutropenia) occurred in about 20% of patients in both groups. Interestingly, patients who ate before taking the drug had fewer vomiting episodes, which may suggest that food could help with tolerability, though this needs confirmation in larger studies.
Regarding cancer response, two patients in the fed-fasted group had partial tumor shrinkage, while six had stable disease (no growth). In the fasted-fed group, seven patients had stable disease. These efficacy results are preliminary given the small sample size and early-stage nature of the trial.
DHP107 represents an improvement over traditional paclitaxel formulations, which require Cremophor EL—a substance that can cause severe allergic reactions and requires careful food timing. Previous cancer drugs in this class often showed significant food effects, meaning patients had to follow strict meal schedules. This new formulation appears to offer more flexibility. The study’s findings align with the goal of developing cancer medicines that fit better into patients’ daily lives without complicated dosing rules.
The study’s main limitation is its small size (25 patients), which is typical for Phase 1 trials but limits how confidently we can apply results to larger populations. The study was open-label, meaning patients and doctors knew the treatment order, which could introduce bias in reporting side effects. The study only tested one dose level (200 mg/m²) and one meal type (high-fat), so results may differ with different doses or meal compositions. The short follow-up period (two cycles) doesn’t tell us about long-term effects. Finally, all participants had advanced cancer, so results may not apply to patients with earlier-stage disease or different cancer types.
The Bottom Line
Based on this research, patients taking DHP107 can take the medication with or without food according to their preference and schedule. There is no need to fast before doses or time meals around medication. However, since some patients experienced less vomiting when eating before the dose, taking it with food might be slightly more comfortable, though this needs confirmation. These recommendations have moderate confidence given the small sample size—larger studies will provide stronger evidence. Patients should always follow their doctor’s specific instructions, as individual factors may warrant personalized guidance.
This finding is most relevant to patients with advanced solid tumors who are candidates for DHP107 treatment. Oncologists prescribing this drug should know that food timing is not a concern. Patients already taking DHP107 can relax meal-timing restrictions. However, these results don’t apply to other cancer drugs, which may have different food interactions. People without cancer don’t need to apply these findings.
The food effect (or lack thereof) would be immediate—the drug’s absorption is the same whether taken with or without food from the first dose onward. Patients wouldn’t need a “break-in period” to see this benefit. However, the cancer-fighting effects and side effects develop over days to weeks as treatment continues.
Frequently Asked Questions
Can I eat before taking DHP107 cancer medication?
Yes, according to a 2026 clinical trial of 25 cancer patients, DHP107 works equally well whether taken with or without food. The drug’s blood levels were 101-105% similar in fed versus fasted conditions, so you can eat whenever you prefer.
Does food affect how much cancer medicine gets into my bloodstream?
For DHP107 specifically, no. A 2026 study found that eating a high-fat meal before the dose didn’t meaningfully change drug absorption. Peak blood levels were nearly identical whether patients fasted or ate, meeting medical standards for no food effect.
Will eating before my DHP107 dose reduce nausea?
Possibly. In a 2026 trial of 25 patients, vomiting occurred in 30.8% of those who fasted but only 8.3% of those who ate before dosing. However, this was a small study, so talk to your doctor about what works best for you individually.
What are the most common side effects of DHP107?
A 2026 trial found diarrhea was most common (41-62% of patients), followed by vomiting (8-31%) and low white blood cell counts (17-23%). Side effect rates varied slightly depending on whether patients ate before the dose.
Is DHP107 better than older paclitaxel cancer drugs?
DHP107 uses a new formulation without Cremophor EL, an ingredient in older versions that caused allergic reactions and required strict food timing. This new version appears to work regardless of food intake, offering more flexibility for patients.
Want to Apply This Research?
- Track medication timing and meal timing separately to identify personal patterns in side effects like nausea or vomiting. Log whether you took DHP107 with food or fasted, then note any nausea, vomiting, or diarrhea in the following 24 hours to see if eating before the dose reduces your symptoms.
- Users can set flexible medication reminders that don’t depend on meal schedules. Instead of “take with breakfast” or “take on empty stomach,” simply set reminders for the prescribed times and take the medication based on your hunger and comfort level.
- Over the first two treatment cycles, track side effect severity (mild/moderate/severe) for nausea, vomiting, and diarrhea in relation to whether you ate before each dose. This personal data helps you and your doctor optimize your individual tolerability, even though the drug’s absorption is the same either way.
This article summarizes research findings from a Phase 1 clinical trial and is for educational purposes only. It does not constitute medical advice. DHP107 is an investigational drug still in clinical testing and is not yet approved for general use. Patients should not make any changes to their cancer treatment or medication schedule without consulting their oncologist. Individual responses to medications vary, and your doctor can provide personalized guidance based on your specific medical situation. Always follow your healthcare provider’s instructions regarding medication timing and food intake.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.